PCMH
SRPT icon

Polymer Capital Management (HK)’s Sarepta Therapeutics SRPT Stock Holding History

Polymer Capital Management (HK)’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,888
Closed -$298K – 203
2024
Q2 		$298K Buy
+1,888
New +$243K 0.06% 130
2024
Q1 		– Sell
-10,000
Closed -$964K – 229
2023
Q4 		$964K Buy
+10,000
New +$959K 0.33% 69

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Polymer Capital Management (HK)'s SRPT Position: Q3 2024 in Review

Polymer Capital Management (HK) sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 1,888 shares — an estimated $298K sold.

Polymer Capital Management (HK) first reported a position in SRPT in Q4 2023 and held it in 2 quarters. The position peaked at $964K in Q4 2023. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Polymer Capital Management (HK) reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Polymer Capital Management (HK) sold 1,888 Sarepta Therapeutics shares in Q3 2024, an estimated $298K.
  • Polymer Capital Management (HK) first reported a position in Sarepta Therapeutics in Q4 2023 and held it in 2 quarters.
  • Polymer Capital Management (HK)'s Sarepta Therapeutics position peaked at $964K in Q4 2023.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Polymer Capital Management (HK)'s 13F filing for Q3 2024, filed 14 Nov 2024.